MATTERHORN supports the global adoption of perioperative durvalumab plus FLOT as a new standard for patients with localized gastric and gastroesophageal junction adenocarcinoma,” said Yelena Y.

Detailed price information for Seres Therapeutics Inc (MCRB-Q) from The Globe and Mail including charting and trades.